A healthcare provider may prescribe Bexxar® (tositumomab) to treat certain types of non-Hodgkin's lymphoma, a cancer that begins in the lymphatic system. Bexxar is a synthetic (manufactured) monoclonal antibody.
As part of the treatment regimen, Bexxar is linked to a radioactive element (Iodine I-131). Radioactive treatment such as this is sometimes called radioimmunotherapy.
Bexxar binds to the surface of healthy and certain cancerous cells, signaling the immune system to destroy the cancer cells. In addition, because Bexxar is linked to I-131, it emits radiation that helps destroy both the cancer cell the medicine is attached to and surrounding cancer cells.
(Click Bexxar for more details on how this drug works to help destroy cancer cells. This article also discusses possible side effects, dosing guidelines, and safety precautions.)
Written by/reviewed by: Kristi Monson, PharmD;Arthur Schoenstadt, MD
Last reviewed by: KristiMonson, PharmD;
List of references (click here):
Bexxar [package insert]. Research Triangle Park, NC: GlaxoSmithKline;2012 August.
Bexxar Web site. Available at: http://www.bexxar.com/. Accessed December 15, 2011.
Food and Drug Administration, Center for Drug Evaluation and Research. FDA approved drug products. FDA Web site. Available at: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/. Accessed December 15, 2011.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind.
Site users seeking medical advice about their specific situation should consult with their own physician. Click